Inventor · disambiguated record
Garrick Packard
Also filed as: PACKARD GARRICK · PACKARD GARRICK K · PACKARD Garrick Kenneth
20 granted patents·13 pending applications·554 citations·filing 2002–2024
96Inventor score
Files withSIGNAL PHARM LLC10EFFECTOR THERAPEUTICS INC7LYCIA THERAPEUTICS INC5PERRIN-NINKOVIC SOPHIE3BAHMANYAR SOGOLE2
Top patents by PatentIndex Score
33 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0297US6831175B2Kinase inhibitorsABBOTT LAB·Filed 2002·Granted Dec 14, 2004·214 cites·21 claims
- 0396US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0496US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0595US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0693US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0791US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 0888US10577378B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·6 cites·14 claims
- 0988US9957277B2eIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·6 cites·14 claims
- 1088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 1187US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 1284US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 1384US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 1483US11440917B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Sep 13, 2022·1 cites·19 claims
- 1582US2023295179A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1680US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 1780US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1879US11286268B1EIF4E-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·1 cites·28 claims
- 1977US2023071483A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2074US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 2172US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 2271US12258332B2ASGPR cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2023·Granted Mar 25, 2025·0 cites·18 claims
- 2371US2025101007A1Asgpr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2470US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 2566US2025064941A1Siglec ligands, conjugates, and methods of use thereofOSPREY BIOPHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2663US2023108594A1Eif4e-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2755US2024335544A1M6pr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2854US2023234943A1Trex1 inhibitors and uses thereofTEMPEST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2953US2024165250A1Bifunctional Folate Receptor Binding CompoundsLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3048US2023158155A1Cell Surface Receptor Binding Compounds and ConjugatesLYCIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3146US2003187026A1Kinase inhibitorsFiled 2002·Application pending·0 cites
- 3244US2008004271A1Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewithMCKENNA JEFFREY M·Filed 2007·Application pending·0 cites
- 3343US2013005707A1Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →